ProCE Banner Activity

New Evidence and Novel Therapeutic Strategies in Myelofibrosis Care: Key Presentations at ASH 2023

PDF

Download this list of key presentations at ASH 2023 related to evidence-based strategies in the care of patients with myelofibrosis.

Released: November 29, 2023

Share

Faculty

Jean-Jacques Kiladjian

Jean-Jacques Kiladjian, MD, PhD

Professor
Department of Clinical Pharmacology
Université de Paris
Professor
Clinical Investigations Center
Saint-Louis Hospital
Paris, France

Abdulraheem Yacoub

Abdulraheem Yacoub, MD

Professor
The Division of Hematologic Malignancies and Cellular Therapeutics
University of Kansas Medical Center
The University of Kansas Health System
Westwood, Kansas

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from CTI BioPharma Corp, Geron Corporation, GlaxoSmithKline LLC, and Karyopharm Therapeutics Inc.

CTI BioPharma Corp., a Sobi Company

Geron Corporation

GlaxoSmithKline LLC

Karyopharm Therapeutics Inc.

Disclosure

Primary Author

Jean-Jacques Kiladjian, MD, PhD

Professor
Department of Clinical Pharmacology
Université de Paris
Professor
Clinical Investigations Center
Saint-Louis Hospital
Paris, France

Jean-Jacques Kiladijan, MD, PhD: consultant/advisor/speaker: AbbVie, AOP Health, Bristol Myers Squibb, GlaxoSmithKline, Incyte, Novartis, Pharmaessentia.

Abdulraheem Yacoub, MD

Professor
The Division of Hematologic Malignancies and Cellular Therapeutics
University of Kansas Medical Center
The University of Kansas Health System
Westwood, Kansas

Abdulraheem Yacoub, MD: consultant/advisor/speaker: AbbVie, Acceleron, Apellis, Blueprint Medicine, CTI Pharma, Gilead, GlaxoSmithKline, Incyte, Karyopharm Therapeutics, Notable Labs, Novartis, Pfizer, PharmaEssentia, Protagonist, Servier.